Kornimate/medical-research-clean huggingface dataset:
systemic chemotherapy combined with recombinant human adenovirus type 5 and endostatin injections for treatment malignant hydrothorax in nsclc patients

Conditions: Malignant Hydrothorax; Non Small Cell Lung Cancer

Summary: the purpose of this multi-center clinical trial is to verify more effective on local control of malignant pleural effusions in nsclc patients by thoracic cavity perfusion of recombinant human adenovirus type 5 injection and recombinant human endostatin injection (endostar) compared with cisplatin perfusion, with acceptable side effects.

malignant pleural effusion, which can malfunction of circulatory and respiratory systems, is a common complication in advanced nsclc, finally decreases the quality of life and lifespan. nowadays, it is still a challenge to effectively control malignant pleural effusion. in this multi-center randomized and controlled clinical trial, 134 nsclc patients diagnosed as malignant pleural effusion in the first time will enroll. based on systemic chemotherapy and pleural cavity perfusion, all eligible patients are randomly assigned into treatment group (recombinant human adenovirus type 5 and endostatin injections) and control group (cisplatin) with ratio 1:1. local control rate and side effects are record respectively. the anticipation is that treatment group obtains faster and longer control of pleural effusion.

Eligibility criteria:
inclusion criteria: 1. age 18-75 yrs; 2. kamofsky score (kps) ≥70, and a predicted lifespan \>3 months; 3. enough function of vital organs, such as heart, liver and kidney; 4. advanced nsclc diagnosed by cytology or pathology 5. unilateral or bilateral of malignant pleural effusion in the first time; 6. patients who are considered as malignant pleural effusion by cytology or biomarkers (cea, ca199, ca125) in pleural effusion; 7. without systemic infection or high fever; 8. without active egfr mutation or unwilling to targeted molecular therapy; 9. no anti tumor radiotherapy chemotherapy and molecular targeted therapy,or received anti tumor radiotherapy chemotherapy and molecular and clinical remission more than three months and in the past month ,disease progress with pleural cavity effusion but haven't use systemic or local anti tumor treatment. 10. no pleural cavity injection of antineoplastic drugs. exclusion criteria: 1. non-malignant pleural effusion; 2. pleural effusion cause by other malignant tumors; 3. allergic to recombinant human adenovirus type 5 injection or endostar; 4. pregnant or lactation women; 5. previously using medicine for treating nsclc with pleural cavity effusion by systemic or pleural cavity perfusion treatment one month prior to enrollment; 6. previously using the diuretics, albumin and anti-angiogenesis drugs, or dexamethasone one month prior to enrollment.
study comparing the efficacy and safety of abt-874 to etanercept and placebo in subjects with moderate to severe chronic plaque psoriasis

Conditions: Plaque Psoriasis

Summary: compare the efficacy of abt-874 versus etanercept in subjects with moderate to severe plaque psoriasis


Eligibility criteria:
inclusion criteria: * diagnosis of psoriasis for 6 mo. * bsa 10%, pasi 12 or above, pga 3 or above exclusion criteria: * previous exposure to either etanercept or abt-874
effect of modified stylet angulation on the intubation with glidescope®

Conditions: Cholecystitis; Stomach Cancer

Summary: the glidescope® videolaryngoscope usually visualize glottis better than the conventional laryngoscope. under the visualization of glottis by glidescope®, the insertion of endotracheal tube, however, is challenging. the goal of this study was to determine which of two stylet (70° vs 90°) was better, as determined by time to intubation.


Eligibility criteria:
inclusion criteria: * patients requiring endotracheal intubation for general anesthesia exclusion criteria: * difficult airway * rapid sequence induction * recent sore throat * fragile teeth * contraindication for videolaryngoscope * head and neck surgery

Keywords: intubation stylet videolaryngoscope
chlamidia antibodies test for tubal factor screening

Conditions: Sterility

Summary: the aim of this study is to evaluate the usefulness of a chlamydia antibody test for screening of tubal factor in patients who undergo artificial insemination.


Eligibility criteria:
inclusion criteria: * age \< 38 years * fsh \< 12. * treatment intrauterine insemination exclusion criteria: * insulin dependent diabetes * thyroid disease * severe male factor * policystic ovarian syndrome * previous abdominal or uterine surgery * prevous abdominal or genital infections * uterine myomas * hidrosalpinx * uterine congenital abnormalities

Keywords: chlamidia antibody test, hysterosalpyngography, tubal disease
magnesium loading in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: dietary magnesium (mg) intake has been shown to be independently related to lung function, airway reactivity, and respiratory symptoms in the general population. inhaled mg and iv mg administration have been shown to promote bronchodilation and to improve lung function in asthmatic patients. some studies have suggested that copd patients exhibit decreased body levels of mg. the purpose of the present study was to investigate the effects of acute iv mg loading on parameters of respiratory function and maximal exercise capacity of stable copd patients.the study hypothesis is that mg administration will be associated to improvements on airflow and vasodilation leading to improvements of pulmonary function and exercise performance.

patients are required to have a diagnosis of copd according to the global initiative for chronic obstructive lung disease criteria. this is a randomized, double-blind, placebo-controlled, cross-over study. twenty five patients are going to be included. they are going to come to the laboratory to receive iv placebo or iv mg sulfate at two distinct occasions about 48 hours apart. half of the patients are going to receive mg first and placebo at the second day, while the other half are going to receive the treatments in an inverse order. tests are going to be performed before and about 40 minutes after the iv infusions. tests to be performed are: spirometry, arterial blood gases, mg plasma level measurements, and a maximal exercise test protocol in cycloergometer.

Eligibility criteria:
inclusion criteria: * copd diagnosis according gold criteria * men between 45 and 80 years old exclusion criteria: * history of asthma or atopy, renal failure, heart failure, arrhythmias or cardiac electrical disturbances, and other significant disease other than copd. * individuals on chronic oral steroids, diuretics, or use of mineral supplementation. * locomotor impairment.

Keywords: copd magnesium pulmonary function exercise physiology
study to investigate if adding lactulose to vitamin d and calcium has an effect on the preservation of bone in postmenopausal women

Conditions: Osteopenia

Summary: this is a randomized, double-blind, multicentre, parallel pilot clinical trial to study the efficacy of a treatment of lactulose 15 ml + vitamin d 400 u + calcium 0.5 g compared to lactulose placebo 15 ml + vitamin d 400 u + calcium 1 g in bone mass preservation among postmenopausal women.


Eligibility criteria:
inclusion criteria: women aged between 55 and 65 years old; postmenopausal who have amenorrhea for 5 or more years; women with the diagnosis of osteopenia defined dmo -1,5 to -2,5 exclusion criteria: any disease causing osteopenia (hyperthyroidism, hyperparathyroidism, hypercortisolism, osteogenesis imperfecta, rheumatoid arthritis, homocystinuria, etc.)

Keywords: lactulose; randomised clinical trial; osteopenia; postmenopause
effect of exercise training on breastmilk composition

Conditions: Obesity

Summary: the aim of this trial is to investigate whether regular endurance exercise during the lactation period will influence breastmilk composition among individuals with overweight/obesity, and secondarily to assess if such changes impact the growth and health of the infants.


Eligibility criteria:
inclusion criteria: * female * aged 18 years or older * body mass index ≥ 25 kg/m2 pre-pregnancy and/or bmi ≥ 28 kg/m2 postpartum * given birth to a singleton term (after 37 weeks + 0 days) baby * 6-7 weeks postpartum at time of inclusion * exclusively breastfeeding the baby (no other foods are given) and intend to continue this practice for ≥ 8 weeks at inclusion * understands oral and written norwegian exclusion criteria: * on-going pregnancy * known type 1 or type 2 diabetes * known cardiovascular disease * high intensity exercise more than twice weekly the last three months before inclusion and/or an intention to start regular endurance training within the next 8 weeks at baseline
study to evaluate the effect of the treatment with micardis® or micardisplus® on blood pressure

Conditions: Hypertension

Summary: the primary objective was to evaluate the effect of the treatment with micardis® or micardisplus® on blood pressure. secondary objectives were the effect of micardis® / micardisplus® on metabolic parameters (triglycerides, cholesterol, ldl blood glucose, insulin homeostasis model assessment (homa)-index and hba1c) in patients with essential hypertension and diabetes mellitus


Eligibility criteria:
inclusion criteria: * age \> 18 years * hypertension * diabetes mellitus exclusion criteria: * age \< 18 years
zenith® p-branch™: single-center study

Conditions: Aortic Aneurysm; Abdominal Aortic Aneurysm

Summary: the zenith® p-branch™: single-center study is a clinical trial approved by swedish regulatory authority to study the safety and effectiveness of the zenith® p-branch™ in the treatment of abdominal aortic aneurysms.


Eligibility criteria:
inclusion criteria: * pararenal or juxtarenal aaa \>5.0 cm in diameter * pararenal or juxtarenal aaa with history of growth \>0.5 cm/year exclusion criteria: * age \< 18 years * life expectancy \< 2 years * pregnant or breast feeding * inability or refusal to give informed consent by the patient or a legally authorized representative * unwilling or unable to comply with the follow-up schedule * additional medical restrictions as specified in the clinical investigation plan * additional anatomical restrictions as specified in the clinical investigation plan

Keywords: abdominal aortic aneurysm endovascular fenestration juxtarenal off-the-shelf pararenal
ivf treatment in women with immature oocytes in previous cycle

Conditions: Infertility

Summary: in standard ivf stimulation cycle,human chorionic gonadotropin (hcg) is usually used at the end of controlled ovarian hyperstimulation (coh) as a surrogate to only the luteinizing hormone (lh) surge. yet, the last dose of follicle stimulating hormone (fsh) is usually given between 12-24 hours before the hcg triggering dose.one protocol used at the investigators unit, after a cycle with low proportion of mature oocytes per number oocytes retrieved, is triggering with high dose hcg (500 mcg)-38 hours prior to oocyte aspiration. lately, new researches showed that dual triggering of final oocyte maturation with a combination of gnrh- agonist and hcg, could improve the live-birth rate of normal responders undergoing the gnrh-antagonist coh protocol another treatment option is high dose hcg. only few case reports have described the use of high dose hcg after aspiration of non mature oocytes at a previous cycle. at the investigators ivf unit, patients with previous history of high percentage of immature oocytes retrieved, are triggered at the following cycle, either with double trigger or with high dose of hcg decided by the physician consulting the patient. it is still not known with which way of triggering more mature oocytes is retrieved. the aim of this study is to perform a prospective randomized controlled study in patients with low proportion of mature-mii oocytes oocytes (\<75%) per number oocytes retrieved, despite normal response to controlled ovarian hyperstimulation ( coh ) comparing cycles triggered with high dose hcg to those triggered with hcg+gnrh agonist.

patients will be prospectively randomized into two groups. the randomization will be organized through the computer. the hcg group- will be triggered for final follicular maturation with high dose hcg (500 mcg)-38 hours prior to oocyte aspiration, and the double trigger group- will receive gonadotropin-releasing hormone (gnrh) agonist (decapeptyl 0.2mg) 40 hours prior to oocyte aspiration and hcg (250mcg) 34 hours prior to the oocyte aspiration. all patients will be supplemented with the same progesterone preparation( crinone gel 8% once a day) for luteal support. women that suffer from vaginal spotting or vaginal bleeding during the luteal phase will receive supplementation of geston 50mg intramuscular once every 2 days. at the day of oocyte aspiration, blood will be drawn for serum lh, fsh, estrogen (e2) and progesterone. moreover, clear follicular fluid will be collected and tested for lh, fsh, e2 and progesterone levels.

Eligibility criteria:
inclusion criteria: * patients with low proportion of mature-mii oocytes oocytes (75%) per number oocytes retrieved at the prior ivf cycle * age between 18-42 exclusion criteria: * women with high ovarian response:anti-mullerian hormone ( amh) \>5, antral follicle count ( afc) \>15 * more than 20 oocytes retrieved at the prior cycle.

Keywords: double triggering oocyte maturation gnrh agonist hcg ivf treatment immature oocytes
the effects of different lipid emulsions on the adipokines in critically ill patients with sepsis

Conditions: Sepsis

Summary: intravenous lipid emulsions contain a number of biologically active ingredients, but the most important are fatty acids. different fatty acids can affect a number of different physiological processes in different ways in critically ill patients. adipose tissue can play an important role in metabolic changes of critical illnesses and in adaptation to stress through structural as well as functional changes although it is known that serum adipokine and cytokine response changes in critical sepsis patients, the factors affecting these changes and the metabolic consequences of these changes are not well defined. the aim of this study was to evaluate the effects of intravenous lipid emulsions on serum adipokine and cytokine levels in patients with sepsis. secondly, this is to determine the adipokine and cytokine kinetics in the sepsis process and their relationship with mortality in patients with sepsis.


Eligibility criteria:
inclusion criteria: * diagnosis of sepsis within the last 24 h * age above 18 and below 85 years * indication of only parenteral nutrition therapy exclusion criteria: * planning any different medical nutrition therapy such as enteral nutrition, immunonutrition or oral nutrition * hypersensitivity (fish, egg or soy protein) * uncontrolled hemorrhage * uncontrolled hyperlipidemia * severe primary blood coagulation diseases * acute pancreatitis * acute thromboembolic diseases * severe liver failure * rifle stage iii and iv renal failure * pregnancy or lactation * expected stay in icu not more than 10 days * expected survival not more than 10 days

Keywords: parenteral nutrition sepsis adipokines inflammation intensive care
examining a text message intervention for smoking cessation

Conditions: Tobacco Use Disorder; Nicotine Dependence

Summary: the primary goal of this study is to use qualitative interviews and focus groups to aid us in adapting a face-to-face smoking cessation intervention for delivery through text messaging. after design is completed, the intervention will be pilot tested with a sample of young adults (ages 18-35) who smoke. final assessments will be conducted at 7 weeks (end of treatment) and both 3 and 6 month follow up.


Eligibility criteria:
inclusion criteria: * age 18 to 35 * current daily smoker * has a cell phone with text messaging capability * uses text messaging at least once monthly * interested in quitting smoking * willing to set a quit date within the next 30 days * has access to a physician exclusion criteria: * does not read and speak english with adequate comprehension * is currently participating in a smoking cessation program * concurrent drug/alcohol abuse * mental health issues that would interfere with study compliance

Keywords: tobacco smoking text message therapy
gabapentin's effects on insomnia in patients with recent concussion

Conditions: Insomnia

Summary: in this open-label, pilot study the investigators will be assessing gabapentin's effects on insomnia and other concussion-related symptoms in patients with a recent concussion experiencing insomnia.


Eligibility criteria:
inclusion criteria: 1. head trauma causing concussion with either no loss of consciousness (loc) or loc \< 30 minutes within previous 2 weeks. 2. iss score at baseline of \> 14. 3. pcss score at baseline \> 5. 4. if brain imaging has been checked, there was no intracerebral hemorrhage noted. 5. glasgow coma scale score of 15 at baseline. 6. age of at least 14 years old. 7. has not taken gabapentin or pregabalin any time since concussion and has no history of intolerance to gabapentin or pregabalin. 8. has not taken any sleeping pills for previous 2 nights and agrees not to take any for the next 2 weeks. exclusion criteria:

Keywords: concussion gabapentin neurontin insomnia
intramuscular epinephrine as an adjunctive treatment for severe pediatric asthma exacerbation

Conditions: Asthma

Summary: project aim: to determine if intramuscular epinephrine is an effective adjunct to inhaled bronchodilators (β2 agonists) for children with severe asthma exacerbation. hypothesis: im epinephrine is an efficacious adjunct to inhaled bronchodilators (β2 agonists) for children with severe asthma exacerbation. intervention: subjects will be randomly assigned (50% chance) to receive a weight based dose of im epinephrine 1:1000 or no adjunctive medication. the dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. this will be injected intramuscularly by an ed nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle. in addition to the study intervention, the standardized treatment pathway based on the current asthma guidelines in use at the investigator's center will be utilized. this pathway includes nebulized albuterol, ipratropium bromide, and systemic corticosteroids. the duration and dosages of these other interventions will be administered at the discretion of the treating provider.


Eligibility criteria:
inclusion criteria: 1. age greater than 6 years and less than 18 years 2. pre-existing diagnosis of asthma 3. presenting to the ed with an asthma exacerbation exclusion criteria: 1. history of chronic lung or upper airway disease other than asthma 2. history significant, uncorrected congenital heart disease or cardiac arrhythmia 3. history of thyroid disease 4. impending respiratory failure 5. allergy to epinephrine 6. pregnancy 7. pefr\>60% of predicted and clinical asthma score less than 8

Keywords: status asthmaticus asthma exacerbation epinephrine adjunctive therapy
families and pediatric cardiac surgery multidisciplinary teams: how well do we communicate

Conditions: Communication

Summary: purpose: -to evaluate the peri-operative communication between families and the pediatric cardiac surgery team. method: -in this study the investigators plan to utilize structured interview and survey of parents/legal guardians and health care providers of children undergoing cardiac surgery in the united states of america.

every day clinicians face challenges when attempting to negotiate their way through dialogues with families whose children require surgical intervention in the near future. the area of clinician-patient communication with pediatric families is under-researched and highlights a pressing clinical problem. there are several adult studies that describe the content and nature of patient-physician communications at the time of cardiac surgery. however, there are no studies that evaluate the communications between nursing, physicians, and pediatric patient's families at the time of cardiac surgery. further knowledge in this area is valuable in that a disparity between the these groups can lead to medical error, damage the clinician-patient relationship and provide grounds for dissatisfaction, complaints, or claim. this research will provide insight into what patient's families value in their communications with the medical team and assist the medical community in better meeting our children's families needs.

Eligibility criteria:
inclusion criteria: * primary language is english * \> 18 years age * nurse, physician, physician assistant, or parent / legal guardian of a pediatric patient who requires cardiothoracic surgery at the north carolina children's hospital. exclusion criteria: * primary language is not english. the interviewers all speak english as their primary language. people whose primary language is other than english will only be excluded if they do not have the ability to converse in english with the interviewers. * \<18 years of age. the parent / legal guardian must be of age to be the primary caregiver able to make decisions for their child. * people with an intellectual or mental impairment that prohibits their capacity to make medical decisions for their child. our research aims to investigate the relationship between the parent / legal guardians of pediatric cardiac surgery patients who interact with the pediatric cardiac surgery multidisciplinary team. these individuals must have sufficient mental capacity to be able to provide consent for their child to undergo surgery. individuals with intellectual or mental impairment that prohibits their ability to give consent are therefore excluded.

Keywords: congenital cardiac disease teamwork communication peri-operative
investigation of metabolomics differences between metabolic syndrome and healthy individuals in taiwan

Conditions: Metabolic Syndrome

Summary: the prevalence of metabolic syndrome in taiwan has been increasing yearly. in this project, the database of blood test results from healthy and metabolic syndromes individuals will be analyzed to identify the small molecules related to the severity of metabolic syndrome. these identified small molecules could be used as biomarkers to predict the development of metabolic syndromes in the future.


Eligibility criteria:
inclusion criteria: * capable adults weigh ≥ 50 kg exclusion criteria: * not taiwanese * having received oral antibiotics, immunosuppressants, and chemotherapy drugs in the past month * incapacity * limited disposing capacity * mental disorders or intellectual disabilities